



Specimen Information

G2300072

Date Collected: 10/04/2023

Date Received: 10/04/2023 11:08

Date Reported: 10/04/2023 11:39

Date of Last Injection: 09/28/2023 15:00

601 Biotech Dr. Suite 301 Richmond, VA 23235

Phone: (844) 347-2643

ww.grangergenetics.com

Fax: (804) 977-5041

Patient Information

Physician Information

Name: Sample Patient

Physician Test

Date of Birth: 07/20/2000 Age: 23Y Gender: M

Test Agency

Patient MRN: SampleMRN

601 BioTech Dr Suite 301

Sample ID: ExternalSampleID

North Chesterfield, VA 23235

CPT Codes: 82657, 83516

(844) 347-2643

Asparaginase Panel-Unspecified

Calibration of the asparaginase assay is dependent on the exact formulation of L-asparaginase administered to the patient. Reference Range = 0 IU/mL

If the administered drug was Asparlas, the asparaginase activity is: 1.458 IU/mL

If the administered drug was Erwinaze, the asparaginase activity is: 1.689 IU/mL

If the administered drug was Oncaspar, the asparaginase activity is: 2.458 IU/mL

If the administered drug was Rylaze, the asparaginase activity is: 1.789 IU/mL

Asparaginase-Antibodies are: Detected

Assay Methodologies and Limitations of Asparaginase™

Asparaginase Enzyme Activity Quantification Assay utilizes a spectrophotometry/absorbance-based enzyme-coupled kinetic reaction. Measurements of unknown samples are made against a standard curve generated from E. coli L-asparaginase with each run. Calculations for the drug administered and specified were empirically derived and utilize a correction factor that has been correlated to the E. coli L-asparaginase activity. Since Asparaginase concentrations can vary widely from patient to patient there is no reference range for this assay.

The Asparaginase antibody assay is an ELISA based assay and is only intended to report the presence or absence of antibodies against Asparaginase. This assay does not specifically identify neutralizing antibodies. Antibodies should not be present in normal human serum but may be present in patients on Asparaginase therapy.

These tests were developed and their performance characteristics determined by Granger Genetics. Neither assay has been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.